RNA

OmiCure and Ariana Pharma today announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Ariana Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were displayed at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have the potential to expand personalized cancer treatment options for patients with advanced & refractory diseases.

Patients with metastatic urothelial bladder cancer have had few treatment options beyond platinum-based chemotherapies, until the recent introduction of immunotherapy via PD-1 and PD-L1 checkpoint inhibitors. However, checkpoint-inhibitor immunotherapy has been shown to provide significant benefits to a relatively small subset of patients, and in some cases it can cause dangerous side effects such as organ-related inflammation. Hence the need for precision medicine solutions to find biomarkers identifying the patients who might gain the full benefit from these PD-1/PD-L1 inhibitors alone or in combination therapies. A recent study published in Clinical Cancer Research has revealed an RNA-sequencing-based methodology which looks able to do just that.

A recent study published in Nature’s Scientific Reports has shown that progress continues to advance in precision medicine, this time at the intersection of tumor biopsy tissue and RNA sequencing.

The next frontier in precision oncology sits at the intersection of transcriptomics (RNA sequencing), AI technology, and the multiple global validated data sources of existing therapies and clinical trials. As evidenced in the WINTHER trial (Nature Med, April 2019), RNA analysis surfaces actionable data and gives patients and their oncologists the tools to make better treatment decisions about advanced cancers whose biomarkers are hiding in plain sight. This article presents six cases studies from the WINTHER clinical trial to illustrate the power of this new approach to treatment decision-making.

Cancer scientists are going beyond DNA to study RNA and the transcriptome. A recent Omicure et al. article in the Journal of Clinical Colorectal Cancer highlights how RNA sequencing is revealing further characteristics of cancer than those known via DNA. This can potentially lead to additional therapeutic options, particularly once treatment resistance has set in.

Advances in scientific research and technology have all contributed to a decrease in the cancer mortality rate across the world. Still, cancer remains an untamed beast that continues...

Personalized biopsy-driven treatment based on DNA sequencing has been tested in various settings for over ten years. Unfortunately, the response rate is disappointing. A recent study shows that profiling RNA, instead of DNA, allows the more advanced cancer patients to benefit from personalized therapies, compared to the standard analysis of DNA alterations alone.

OmiCure is excited about the future of precision oncology treatment, thanks to a recent study conducted by the National Cancer Institute. While there is still a considerable amount of...